查看購物車
  • Simplified Chinese
  • English
  • Japanese
2021-2031年北美胃腸藥物市場報告（範圍、細分、動態和競爭分析）
市場調查報告書
商品編碼
1819717

2021-2031年北美胃腸藥物市場報告（範圍、細分、動態和競爭分析）

North America Gastrointestinal Drugs Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 155 Pages | 訂單完成後即時交付

價格

北美胃腸藥物市場預計將大幅成長，到 2031 年將達到 433.6258 億美元，高於 2023 年的 241.044 億美元。這一成長代表著 2023 年至 2031 年的年複合成長率(CAGR) 為 7.6%。

執行摘要和市場分析

北美胃腸藥物市場主要分為三個區域：美國、加拿大和墨西哥。推動該市場成長的因素包括：生活方式改變導致的胃腸疾病發病率上升、政府訂定的預防和治療胃腸疾病的舉措、健全的醫療基礎設施、蓬勃發展的製藥行業、全面的報銷覆蓋範圍以及大型製藥公司的參與。

市場區隔分析

北美胃腸藥物市場可以透過各個部分進行分析，包括藥物類別、應用、給藥途徑和配銷通路。

1. 藥品類別：市場分為幾類，包括生物製劑、止瀉藥、瀉藥、酸中和劑、抗發炎藥、止吐藥和止吐藥等。 2023年，生物製劑佔據了最大的市場佔有率，反映出其在治療胃腸道疾病的重要性日益增強。

2. 應用：市場也按應用細分，包括腸躁症 (IBS)、發炎性腸道疾病 (IBD)（例如潰瘍性結腸炎和克隆氏症）、胃腸炎、乳糜瀉等。 2023 年，IBS 細分市場佔據最大佔有率，顯示針對該疾病的治療需求龐大。

3. 給藥途徑：胃腸藥物市場分為口服和非腸道給藥途徑。 2023年，口服藥物佔據市場主導地位，因為口服藥物因其便捷易用而更受青睞。

4.配銷通路：胃腸藥物的分銷分為醫院藥房、零售藥房和線上藥房。 2023年，醫院藥局佔據了最大的市場佔有率，凸顯了醫院在藥物分配方面的關鍵作用。

市場展望

近年來，先進療法，尤其是生物製劑的研發蓬勃發展，擴大用於治療發炎性疾病。生物製劑徹底改變了發炎性腸道疾病 (IBD) 的治療格局，其成功也促進了其在其他胃腸道疾病的應用。這些藥物針對免疫系統中導致疾病的特定成分，使其對嗜酸性食道炎、乳糜瀉和自體免疫性肝炎等疾病有效。

生物製劑，尤其是抗腫瘤壞死因子 (TNF) 藥物，在潰瘍性結腸炎和克隆氏症的治療中發揮關鍵作用。這些藥物包括修美樂 (Humira)、辛普尼 (Simponi) 和雷米克 (Remicade) 等知名藥物，其作用機制是阻斷腫瘤壞死因子-α (TNF-α)，一種促進發炎的蛋白質。這些生物製劑的引入顯著改善了發炎性腸道疾病 (IBD) 的治療，許多患者透過使用這些藥物獲得了緩解。 FDA 已批准多種用於治療 IBD 的生物製劑，包括修美樂 (Humira)、欣舒利 (Cimzia)、辛普尼 (Simponi)、泰薩布里 (Tysabri)、雷米克 (Remicade)、恩蒂維奧 (Entyvio) 和斯特拉拉 (Stelara)。值得注意的是，維多珠單抗已成為中度至重度克隆氏症和潰瘍性結腸炎的首選二線生物製劑。

2024年2月，Celltrion Healthcare的Remsima SC獲得加拿大衛生部批准，用於發炎性腸道疾病（IBD）的維持治療，進一步彰顯了該領域的持續創新。發展中國家胃腸道疾病的發生率不斷上升，也推動了對新型生物製劑的需求，從而促進了市場成長。

國家洞察

從地理來看，北美胃腸藥物市場主要由美國、加拿大和墨西哥組成，其中美國在2023年佔據最大市場佔有率。美國胃腸疾病盛行率的上升是推動此類藥物需求的重要因素。克隆氏症和潰瘍性結腸炎等疾病特別常見，根據美國克隆氏症和結腸炎基金會的數據，每年約有7萬例新診斷病例。發炎性腸道疾病（IBD）的總體盛行率從2011年到2020年顯著上升，估計約有240萬美國人受到影響。

預計胃腸道疾病研發資金的增加將加強對新型治療方案的關注。例如，克隆氏症研究在2022年獲得了9,000萬美元的資助，彰顯了推動治療方案的承諾。

美國FDA核准的新藥也有望促進市場成長。例如，2020年5月，FDA核准Qinlock用於治療晚期胃腸道間質瘤；2024年5月，Strides Pharma獲得核准，其學名藥Sucralfate口服混懸液可用於治療多種胃腸道疾病。

公司簡介

北美胃腸藥物市場的主要參與者包括賽諾菲公司、葛蘭素史克公司、強生公司、博士倫公司、阿斯特捷利康公司、武田製藥有限公司、艾伯維公司、拜耳公司、Celltrion公司和輝瑞公司。這些公司正在採用各種策略，包括擴張、產品創新和併購，以增強其市場佔有率並為消費者提供創新解決方案。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：北美胃腸藥物市場格局

  • 概述
  • PEST分析

第5章：北美胃腸藥物市場-關鍵市場動態

  • 市場促進因素
    • 胃腸道疾病病例增加
    • 生物製劑的不斷發展
  • 市場限制
    • 生物製劑成本高
    • 治療嚴重潰瘍性結腸炎或克隆氏症的生物製劑平均費用
  • 市場機會
    • 公司的策略舉措
  • 未來趨勢
    • 加大對新藥開發與人工智慧技術的研究投入
  • 促進因素和限制因素的影響：

第6章：胃腸藥物市場－北美分析

  • 2021-2031年北美胃腸藥物市場收入

第7章：北美胃腸藥物市場分析－依藥物類別

  • 生物製劑
  • 止瀉藥和瀉藥
  • 酸中和劑
  • 抗發炎藥物
  • 止吐藥和止噁心藥
  • 其他

第 8 章：北美胃腸藥物市場分析 - 按應用

  • 急躁性腸症候群
  • 發炎性潰瘍性結腸炎
  • 克隆氏症
  • 胃腸炎
  • 乳糜瀉
  • 其他

第9章：北美胃腸藥物市場分析-依給藥途徑

  • 口服
  • 腸外

第 10 章：北美胃腸藥物市場分析 - 按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 11 章：北美胃腸藥物市場-國家分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第 12 章：產業格局

  • 概述
  • 北美胃腸藥物市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第13章：公司簡介

  • Sanofi SA
  • GSK Plc
  • Johnson & Johnson
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • Takeda Pharmaceutical Co Ltd
  • AbbVie Inc
  • Bayer AG
  • Celltrion Inc
  • Pfizer Inc

第 14 章：附錄

Product Code: TIPRE00016278

The North America gastrointestinal drugs market is projected to grow significantly, reaching an estimated US$ 43,362.58 million by 2031, up from US$ 24,104.40 million in 2023. This growth represents a compound annual growth rate (CAGR) of 7.6% from 2023 to 2031.

Executive Summary and Market Analysis

The gastrointestinal drugs market in North America is divided into three primary regions: the United States, Canada, and Mexico. Several factors are driving the growth of this market, including the rising incidence of gastrointestinal disorders linked to lifestyle changes, government initiatives aimed at the prevention and treatment of these diseases, a robust healthcare infrastructure, a thriving pharmaceutical sector, comprehensive reimbursement coverage, and the presence of major pharmaceutical companies.

Market Segmentation Analysis

The North America gastrointestinal drugs market can be analyzed through various segments, including drug class, application, route of administration, and distribution channel.

1. Drug Class: The market is categorized into several drug classes, including biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, among others. In 2023, biologics accounted for the largest market share, reflecting their growing importance in treating gastrointestinal conditions.

2. Application: The market is also segmented by application, which includes conditions such as irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease, gastroenteritis, celiac disease, and others. The IBS segment held the largest share in 2023, indicating a significant demand for treatments targeting this condition.

3. Route of Administration: The gastrointestinal drugs market is divided into oral and parenteral routes of administration. The oral segment dominated the market in 2023, as oral medications are often preferred for their convenience and ease of use.

4. Distribution Channel: The distribution of gastrointestinal drugs is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies represented the largest share of the market in 2023, highlighting the critical role of hospitals in dispensing these medications.

Market Outlook

Recent years have seen a surge in the development of advanced treatments, particularly biologics, which are increasingly used for managing inflammatory diseases. Biologics have revolutionized the treatment landscape for inflammatory bowel diseases (IBD), and their success has encouraged their application in other gastrointestinal disorders. These drugs target specific elements of the immune system that contribute to disease, making them effective for conditions such as eosinophilic esophagitis, celiac disease, and autoimmune hepatitis.

Biologics, particularly anti-TNF agents, have been pivotal in managing ulcerative colitis and Crohn's disease. These agents, which include well-known medications like Humira, Simponi, and Remicade, work by blocking tumor necrosis factor-alpha (TNF-alpha), a protein that promotes inflammation. The introduction of these biologics has significantly improved the management of IBD, with many patients achieving remission through their use. The FDA has approved numerous biologic drugs for IBD treatment, including Humira, Cimzia, Simponi, Tysabri, Remicade, Entyvio, and Stelara. Notably, Vedolizumab has emerged as a preferred second-line biologic for moderate to severe cases of Crohn's disease and ulcerative colitis.

In February 2024, Celltrion Healthcare's Remsima SC received approval from Health Canada for maintenance therapy in IBD, further illustrating the ongoing innovation in this field. The increasing prevalence of gastrointestinal diseases in developing countries is also driving the demand for new biologics, contributing to market growth.

Country Insights

Geographically, the North American gastrointestinal drugs market is primarily composed of the US, Canada, and Mexico, with the US holding the largest market share in 2023. The rising prevalence of gastrointestinal diseases in the US is a significant factor driving demand for these drugs. Conditions such as Crohn's disease and ulcerative colitis are particularly prevalent, with approximately 70,000 new cases diagnosed annually, according to the Crohn's & Colitis Foundation of America. The overall prevalence of IBD has increased notably from 2011 to 2020, with estimates suggesting that around 2.4 million Americans are affected.

Increased funding for research and development in gastrointestinal diseases is expected to enhance the focus on novel treatment options. For instance, Crohn's disease research received US$ 90 million in funding in 2022, underscoring the commitment to advancing treatment options.

The US FDA's approval of new drugs is also anticipated to bolster market growth. For example, in May 2020, the FDA approved Qinlock for advanced gastrointestinal stromal tumors, and in May 2024, Strides Pharma received approval for a generic version of Sucralfate Oral Suspension for various gastrointestinal conditions.

Company Profiles

Key players in the North America gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, Celltrion Inc, and Pfizer Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. North America Gastrointestinal Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Gastrointestinal Drugs Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Cases of Gastrointestinal Diseases
    • 5.1.2 Increasing Development of Biologics
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Biologics
    • 5.2.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
  • 5.3 Market Opportunities
    • 5.3.1 Strategic Initiatives by Companies
  • 5.4 Future Trends
    • 5.4.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
  • 5.5 Impact of Drivers and Restraints:

6. Gastrointestinal Drugs Market - North America Analysis

  • 6.1 North America Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031

7. North America Gastrointestinal Drugs Market Analysis - by Drug Class

  • 7.1 Biologics
    • 7.1.1 Overview
    • 7.1.2 Biologics: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Antidiarrheal and Laxatives
    • 7.2.1 Overview
    • 7.2.2 Antidiarrheal and Laxatives: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Acid Neutralizers
    • 7.3.1 Overview
    • 7.3.2 Acid Neutralizers: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Anti-inflammatory Drugs
    • 7.4.1 Overview
    • 7.4.2 Anti-inflammatory Drugs: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Antiemetic and Antinauseants
    • 7.5.1 Overview
    • 7.5.2 Antiemetic and Antinauseants: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Gastrointestinal Drugs Market Analysis - by Application

  • 8.1 Irritable Bowel Syndrome
    • 8.1.1 Overview
    • 8.1.2 Irritable Bowel Syndrome: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Inflammatory Ulcerative Colitis
    • 8.2.1 Overview
    • 8.2.2 Inflammatory Ulcerative Colitis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Crohn's Disease
    • 8.3.1 Overview
    • 8.3.2 Crohn's Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Gastroenteritis
    • 8.4.1 Overview
    • 8.4.2 Gastroenteritis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Celiac Disease
    • 8.5.1 Overview
    • 8.5.2 Celiac Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Gastrointestinal Drugs Market Analysis - by Route of Administration

  • 9.1 Oral
    • 9.1.1 Overview
    • 9.1.2 Oral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Parenteral
    • 9.2.1 Overview
    • 9.2.2 Parenteral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Gastrointestinal Drugs Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Retail Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Retail Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Gastrointestinal Drugs Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America Gastrointestinal Drugs Market Overview
    • 11.1.2 North America Gastrointestinal Drugs Market - Breakdown, by Key Countries, 2023 and 2031 (%)
      • 11.1.2.1 United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.1.1 United States: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.1.2.1.2 United States: North America Gastrointestinal Drugs Market Breakdown, by Application
        • 11.1.2.1.3 United States: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.1.2.1.4 United States: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.1.2.2 Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.2.1 Canada: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.1.2.2.2 Canada: North America Gastrointestinal Drugs Market Breakdown, by Application
        • 11.1.2.2.3 Canada: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.1.2.2.4 Canada: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.1.2.3 Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.3.1 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.1.2.3.2 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Application
        • 11.1.2.3.3 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.1.2.3.4 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in North America Gastrointestinal Drugs Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Sanofi SA
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 GSK Plc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Johnson & Johnson
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Bausch Health Companies Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 AstraZeneca Plc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Takeda Pharmaceutical Co Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 AbbVie Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Bayer AG
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Celltrion Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Pfizer Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. North America Gastrointestinal Drugs Market Segmentation
  • Table 2. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 4. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 8. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 12. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Recent Organic Growth Strategies in North America Gastrointestinal Drugs Market
  • Table 15. Recent Inorganic Growth Strategies in the North America Gastrointestinal Drugs Market
  • Table 16. Glossary of Terms, North America Gastrointestinal Drugs Market

List Of Figures

  • Figure 1. North America Gastrointestinal Drugs Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. North America Gastrointestinal Drugs Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 6. North America Gastrointestinal Drugs Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Biologics: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Antidiarrheal and Laxatives: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Acid Neutralizers: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Anti-inflammatory Drugs: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Antiemetic and Antinauseants: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. North America Gastrointestinal Drugs Market Share (%) - by Application (2023 and 2031)
  • Figure 14. Irritable Bowel Syndrome: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Inflammatory Ulcerative Colitis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Crohn's Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Gastroenteritis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Celiac Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. North America Gastrointestinal Drugs Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 21. Oral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Parenteral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. North America Gastrointestinal Drugs Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 24. Hospital Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Retail Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Online Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. North America Gastrointestinal Drugs Market Breakdown, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 28. North America Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 29. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Growth Strategies in North America Gastrointestinal Drugs Market